Monitoring fibrogenic progression in the liver

Clinica Chimica Acta

Volumn 433, Issue , 2014, Pages 111-122

  Gressner, Olav A ^a   Gao, Chunfang ^b,c  

^a Wisplinghoff Medical Laboratories   (Germany)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c Laboratory of Viral and Gene Therapy   (China)

Author keywords

Biological markers; Blood chemical analysis; Cytokines; Liver cirrhosis; Serologic tests

Indexed keywords

BIOLOGICAL MARKER; COLONY STIMULATING FACTOR 1; CONNECTIVE TISSUE GROWTH FACTOR; GLYCAN; GLYCOPROTEIN; GLYCOSAMINOGLYCAN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYALURONIC ACID; LAMININ; OSTEOGENIC PROTEIN 1; PROTEIN YKL 40; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; XYLOSYLTRANSFERASE;

AREA UNDER THE CURVE; BONE MARROW CELL; CELL DIFFERENTIATION; CELL SURVIVAL; CELL TRANSDIFFERENTIATION; DIAGNOSTIC ACCURACY; DISEASE COURSE; DISEASE MARKER; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; FIBROGENESIS; FLOW CYTOMETRY; GLYCOBIOLOGY; HUMAN; IMMUNOASSAY; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER FIBROSIS; MASS SPECTROMETRY; MONOCYTE; MYOFIBROBLAST; PATHOGENESIS; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; PROTHROMBIN TIME; REVIEW; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; STELLATE CELL; THROMBOCYTE COUNT; LIVER; LIVER CIRRHOSIS; METABOLISM;

BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS; LIVER; LIVER CIRRHOSIS;

EID: 84897897694     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.02.021     Document Type: Review

References (164)

1. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
2. Schuppan D., Gressner A.M. Function and metabolism of collagens and other extracellular matrix proteins. Oxford textbook of clinical hepatology 1999, 381-407. Oxford Medical Publications, Oxford, UK. J. Bircher, J.P. Benhamou, N. McIntyre, M. Rizzetto, J. Rodés (Eds.).
3. Schuppan D., Ruehl M., Somasundaram R., Hahn E.G. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis 2001, 21:351-372.
4. Gressner A.M., Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006, 10:76-99.
5. De Caestecker M.P., Piek E., Roberts A.B. Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst 2000, 92:1388-1402.
6. Tsukada S., Parsons C.J., Rippe R.A. Mechanisms of liver fibrosis. Clin Chim Acta 2006, 364:33-60.
7. Bataller R., North K.E., Brenner D.A. Genetic polymorphisms and the progression of liver fibrosis: a critical appraisal. Hepatology 2003, 37:493-503.
8. Gressner O.A., Weiskirchen R., Gressner A.M. Biomarkers of liver fibrosis: clinical translation of molecular pathogenesis or based on liver-dependent malfunction tests. Clin Chim Acta 2007, 381:107-113.
9. Friedman S.L., Rockey D.C., Bissell D.M. Hepatic fibrosis 2006: report of the third AASLD single topic conference. Hepatology 2007, 45:242-249.
10. Gressner A.M. Transdifferentiation of hepatic stellate cells (Ito cells) to myofibroblasts: a key event in hepatic fibrogenesis. Kidney Int 1996, 54:S39-S45.
11. Gressner A.M., Lahme B., Brenzel A. Molecular dissection of the mitogenic effect of hepatocytes on cultured hepatic stellate cells. Hepatology 1995, 22:1507-1518.
12. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. Semin Liver Dis 2001, 21:311-335.
13. Wake K. "Sternzellen" in the liver: perisinusoidal cells with special reference to storage of vitamin A. Am J Anat 1971, 132:429-462.
14. Wake K. Three-dimensional structure of the sinusoidal wall in the liver: a Golgi study. Prog Clin Biol Res 1989, 295:257-262.
15. Marcos R., Rocha E., Henrique R.M., Monteiro R.A. A new approach to an unbiased estimate of the hepatic stellate cell index in the rat liver: an example in healthy conditions. J Histochem Cytochem 2003, 51:1101-1104.
16. Blomhoff R., Wake K. Perisinusoidal stellate cells of the liver: important roles in retinol metabolism and fibrosis. FASEB J 1991, 5:271-277.
17. Winau F., Hegasy G., Weiskirchen R., et al. Ito cells are liver-resident antigen-presenting cells for activating T cell responses. Immunity 2007, 26:117-129.
18. Maubach G., Lim M.C., Kumar S., Zhuo L. Expression and upregulation of cathepsin S and other early molecules required for antigen presentation in activated hepatic stellate cells upon IFN-gamma treatment. Biochim Biophys Acta 2007, 1773:219-231.
19. Vinas O., Bataller R., Sancho-Bru P., et al. Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology 2003, 38:919-929.
20. + hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 2007, 352:410-417.
21. Canbay A., Taimr P., Torok N., Higuchi H., Friedman S., Gores G.J. Apoptotic body engulfment by a human stellate cell line is profibrogenic. Lab Invest 2003, 83:655-663.
22. Zhan S.S., Jiang J.X., Wu J., et al. Phagocytosis of apoptotic bodies by hepatic stellate cells induces NADPH oxidase and is associated with liver fibrosis in vivo. Hepatology 2006, 43:435-443.
23. Benyon R.C., Arthur M.J. Extracellular matrix degradation and the role of hepatic stellate cells. Semin Liver Dis 2001, 21:373-384.
24. Benyon R.C., Iredale J.P., Goddard S., Winwood P.J., Arthur M.J. Expression of tissue inhibitor of metalloproteinases 1 and 2 is increased in fibrotic human liver. Gastroenterology 1996, 110:821-831.
25. Passino M.A., Adams R.A., Sikorski S.L., Akassoglou K. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR. Science 2007, 315:1853-1856.
26. Lee J.S., Semela D., Iredale J., Shah V.H. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte?. Hepatology 2007, 45:817-825.
27. Bataller R., Nicolas J.M., Gines P., et al. Arginine vasopressin induces contraction and stimulates growth of cultured human hepatic stellate cells. Gastroenterology 1997, 113:615-624.
28. Rockey D.C. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337-349.
29. Bataller R., Gines P., Nicolas J.M., et al. Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology 2000, 118:1149-1156.
30. Reynaert H., Thompson M.G., Thomas T., Geerts A. Hepatic stellate cells: role in microcirculation and pathophysiology of portal hypertension. Gut 2002, 50:571-581.
31. Gressner A.M., Chunfang G. A cascade-mechanism of fat storing cell activation forms the basis of the fibrogenic reaction of the liver. Verh Dtsch Ges Pathol 1995, 79:1-14.
32. Gressner A.M., Lotfi S., Gressner G., Lahme B. Identification and partial characterization of a hepatocyte-derived factor promoting proliferation of cultured fat-storing cells (parasinusoidal lipocytes). Hepatology 1992, 16:1250-1266.
33. Gressner A.M., Lotfi S., Gressner G., Haltner E., Kropf J. Synergism between hepatocytes and Kupffer cells in the activation of fat storing cells (perisinusoidal lipocytes). J Hepatol 1993, 19:117-132.
34. Roth S., Michel K., Gressner A.M. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology 1998, 27:1003-1012.
35. Gressner A.M., Lahme B. Treatment of rat hepatocytes with transforming growth factor-beta I increases their mitogenic activity for cultured fat storing cells. Int Hepatol Commun 1995, 4:94-101.
36. Hoffmann C., Lahme B., Brenzel A., Gressner A.M. The relation between hepatocellular damage and activation of fat storing cell proliferation in vitro. Int Hepatol Commun 1994, 2:29-36.
37. Bachem M.G., Melchior R., Gressner A.M. The role of thrombocytes in liver fibrogenesis: effects of platelet lysate and thrombocyte-derived growth factors on the mitogenic activity and glycosaminoglycan synthesis of cultured rat liver fat storing cells. J Clin Chem Clin Biochem 1989, 27:555-565.
38. Decker K. Biologically active products of stimulated liver macrophages (Kupffer cells). Eur J Biochem 1990, 192:245-261.
39. Friedman S.L., Arthur M.J. Activation of cultured rat hepatic lipocytes by Kupffer cell conditioned medium Direct enhancement of matrix synthesis and stimulation of cell proliferation via induction of platelet-derived growth factor receptors. J Clin Invest 1989, 84:1780-1785.
40. Gressner A.M., Haarmann R. Regulation of hyaluronate synthesis in rat liver fat storing cell cultures by Kupffer cells. J Hepatol 1988, 7:310-318.
41. Gressner A.M., Zerbe O. Kupffer cell-mediated induction of synthesis and secretion of proteoglycans by rat liver fat-storing cells in culture. J Hepatol 1987, 5:299-310.
42. Nieto N. Oxidative-stress and IL-6 mediate the fibrogenic effects of [corrected] Kupffer cells on stellate cells. Hepatology 2006, 44:1487-1501.
43. Adachi T., Togashi H., Suzuki A., et al. NAD(P)H oxidase plays a crucial role in PDGF-induced proliferation of hepatic stellate cells. Hepatology 2005, 41:1272-1281.
44. Baroni G.S., D'Ambrosio L., Ferretti G., et al. Fibrogenic effect of oxidative stress on rat heaptic stellate cells. Hepatology 1998, 27:720-726.
45. Casini A., Ceni E., Salzano R., et al. Neutrophil-derived superoxide anion induces lipid peroxidation and stimulates collagen synthesis in human hepatic stellate cells: role of nitric oxide. Hepatology 1997, 25:361-367.
46. Casini A., Cunningham M., Rojkind M., Lieber C.S. Acetaldehyde increases procollagen type I and fibronectin gene transcription in cultured rat fat-storing cells through a protein synthesis-dependent mechanism. Hepatology 1991, 13:758-765.
47. Casini A., Galli G., Salzano R., et al. Acetaldehyde induces c-fos and c-jun proto-oncogenes in fat-storing cell cultures through protein kinase C activation. Alcohol Alcohol 1994, 29:303-314.
48. 2+-independent protein kinase C activation in cultured rat hepatic stellate cells. Alcohol Clin Exp Res 1999, 23:279-284.
49. Svegliati-Baroni G., Ridolfi F., Di Sario A., et al. Intracellular signaling pathways involved in acetaldehyde-induced collagen and fibronectin gene expression in human hepatic stellate cells. Hepatology 2001, 33:1130-1140.
50. Corpechot C., Barbu V., Wendum D., et al. Hypoxia-induced VEGF and collagen I expressions are associated with angiogenesis and fibrogenesis in experimental cirrhosis. Hepatology 2002, 35:1010-1021.
51. Gabele E., Froh M., Arteel G.E., et al. TNFalpha is required for cholestasis-induced liver fibrosis in the mouse. Biochem Biophys Res Commun 2009, 378:348-353.
52. Gressner A.M., Weiskirchen R., Breitkopf K., Dooley S. Roles of TGF-beta in hepatic fibrosis. Front Biosci 2002, 7:d793-d807.
53. Inagaki Y., Okazaki I. Emerging insights into Transforming growth factor beta Smad signal in hepatic fibrogenesis. Gut 2007, 56:284-292.
54. Feige J.J., Baird A. Crinopexy: extracellular regulation of growth factor action. Kidney Int 1995, 49:S15-S18.
55. Pinzani M., Marra F. Cytokine receptors and signaling in hepatic stellate cells. Semin Liver Dis 2001, 21:397-416.
56. Bissell D.M., Wang S.S., Jarnagin W.R., Roll F.J. Cell-specific expression of transforming growth factor-beta in rat liver evidence for autocrine regulation of hepatocyte proliferation. J Clin Invest 1995, 96:447-455.
57. Marra F., Bonewald L.F., Park-Snyder S., Park I.S., Woodruff K.A., Abboud H.E. Characterization and regulation of the latent transforming growth factor-beta complex secreted by vascular pericytes. J Cell Physiol 1996, 166:537-546.
58. Gressner A.M., Polzar B., Lahme B., Mannherz H.G. Induction of rat liver parenchymal cell apoptosis by hepatic myofibroblasts via transforming growth factor beta. Hepatology 1996, 23:571-581.
59. Gressner A.M., Lahme B., Mannherz H.G., Polzar B. TGF-beta-mediated hepatocellular apoptosis by rat and human hepatoma cells and primary rat hepatocytes. J Hepatol 1997, 26:1079-1092.
60. Kiso S., Kawata S., Tamura S., et al. Alteration in growth regulation of hepatocytes in primary culture obtained from cirrhotic rat: poor response to transforming growth factor-beta 1 and interferons. Hepatology 1994, 20:1303-1308.
61. Bissell D.M., Roulot D., George J. Transforming growth factor beta and the liver. Hepatology 2001, 34:859-867.
62. Koli K., Saharinen J., Hyytiainen M., Penttinen C., Keski-Oja J. Latency, activation, and binding proteins of TGF-beta. Microsc Res Tech 2001, 52:354-362.
63. Arias M., Lahme B., Van de Leur E., Gressner A.M., Weiskirchen R. Adenoviral delivery of an antisense RNA complementary to the 3' coding sequence of transforming growth factor-beta1 inhibits fibrogenic activities of hepatic stellate cells. Cell Growth Differ 2002, 13:265-273.
64. de Gouville A.C., Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. Drug News Perspect 2006, 19:85-90.
65. Dooley S., Delvoux B., Lahme B., Mangasser-Stephan K., Gressner A.M. Modulation of transforming growth factor beta response and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000, 31:1094-1106.
66. Hellerbrand C., Stefanovic B., Giordano F., Burchardt E.R., Brenner D.A. The role of TGFbeta1 in initiating hepatic stellate cell activation in vivo. J Hepatol 1999, 30:77-87.
67. Iwamoto H., Sakai H., Nawata H. Inhibition of integrin signaling with Arg-Gly-Asp motifs in rat hepatic stellate cells. J Hepatol 1998, 29:752-759.
68. Geerts A., Vrijsen R., Rauterberg J., Burt A., Schellinck P., Wisse E. In vitro differentiation of fat-storing cells parallels marked increase of collagen synthesis and secretion. J Hepatol 1989, 9:59-68.
69. Liu J.J., Hu T., Wu X.Y., et al. Peroxisome proliferator-activated receptor-gamma agonist rosiglitazone-induced apoptosis in leukemia k562 cells and its mechanisms of action. Int J Toxicol 2009, 28:123-131.
70. Shi H.Y., Ge J.B., Fang W.Y., et al. Peroxisome proliferator-activated receptor alpha agonist attenuates oxidized-low density lipoprotein induced immune maturation of human monocyte-derived dendritic cells. Chin Med J 2008, 121:1747-1750.
71. Sun K., Wang Q., Huang X.H. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression. Acta Pharmacol Sin 2006, 27:715-723.
72. De Minicis S., Seki E., Uchinami H., et al. Gene expression profiles during hepatic stellate cell activation in culture and in vivo. Gastroenterology 2007, 132:1937-1946.
73. Wake K., Sato T. Intralobular heterogeneity of perisinusoidal stellate cells in porcine liver. Cell Tissue Res 1993, 273:227-237.
74. Ballardini G., Groff P., Badiali de Giorgi L., Schuppan D., Bianchi F.B. Ito cell heterogeneity: desmin-negative Ito cells in normal rat liver. Hepatology 1994, 19:440-446.
75. Zou Z., Ekataksin W., Wake K. Zonal and regional differences identified from precision mapping of vitamin A-storing lipid droplets of the hepatic stellate cells in pig liver: a novel concept of addressing the intralobular area of heterogeneity. Hepatology 1998, 27:1098-1108.
76. Horn T., Junge J., Christoffersen P. Early alcoholic liver injury. Activation of lipocytes in acinar zone 3 and correlation to degree of collagen formation in the Disse space. J Hepatol 1986, 3:333-340.
77. Knittel T., Kobold D., Piscaglia F., et al. Localization of liver myofibroblasts and hepatic stellate cells in normal and diseased rat livers: distinct roles of (myo-)fibroblast subpopulations in hepatic tissue repair. Histochem Cell Biol 1999, 112:387-401.
78. Knittel T., Kobold D., Saile B., et al. Rat liver myofibroblasts and hepatic stellate cells: different cell populations of the fibroblast lineage with fibrogenic potential. Gastroenterology 1999, 117:1205-1221.
79. Kobold D., Grundmann A., Piscaglia F., et al. Expression of reelin in hepatic stellate cells and during hepatic tissue repair: a novel marker for the differentiation of HSC from other liver myofibroblasts. J Hepatol 2002, 36:607-613.
80. Magness S.T., Bataller R., Yang L., Brenner D.A. A dual reporter gene transgenic mouse demonstrates heterogeneity in hepatic fibrogenic cell populations. Hepatology Hepatology (Baltimore, Md 2004, 40:1151-1159.
81. Cassiman D., Roskams T. Beauty is in the eye of the beholder: emerging concepts and pitfalls in hepatic stellate cell research. J Hepatol 2002, 37:527-535.
82. Collazos J., Diaz F. Role of the measurement of serum procollagen type III N-terminal peptide in the evaluation of liver diseases. Clin Chim Acta 1994, 227:37-43.
83. Lydatakis H., Hager I.P., Kostadelou E., Mpousmpoulas S., Pappas S., Diamantis I. Non-invasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006, 26:864-871.
84. Kropf J., Gressner A.M., Tittor W. Logistic-regression model for assessing portal hypertension by measuring hyaluronic acid (hyaluronan) and laminin in serum. Clin Chem 1991, 37:30-35.
85. Flisiak R., Maxwell P., Prokopowicz D., Timms P.M., Panasiuk A. Plasma tissue inhibitor of metalloproteinases-1 and transforming growth factor beta 1-possible non-invasive biomarkers of hepatic fibrosis in patients with chronic B and C hepatitis. Hepatogastroenterology 2002, 49:1369-1372.
86. Breitkopf K., Lahme B., Tag C.G., Gressner A.M. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001, 33:387-396.
87. Hyytiainen M., Penttinen C., Keski-Oja J. Latent TGF-beta binding proteins: extracellular matrix association and roles in TGF-beta activation. Crit Rev Clin Lab Sci 2004, 41:233-264.
88. Crookston K.P., Webb D.J., Lamarre J., Gonias S.L. Binding of platelet-derived growth factor-BB and transforming growth factor-beta 1 to alpha 2-macroglobulin in vitro and in vivo: comparison of receptor-recognized and non-recognized alpha 2-macroglobulin conformations. Biochem J 1993, 293(Pt 2):443-450.
89. Grainger D.J., Mosedale D.E., Metcalfe J.C. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev 2000, 11:133-145.
90. Poynard T., Imbert-Bismut F., Munteanu M., et al. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004, 3:8.
91. Wai C.T., Greenson J.K., Fontana R.J., et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526.
92. Rosenberg W.M., Voelker M., Thiel R., et al. Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713.
93. Adams L.A., Bulsara M., Rossi E., et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867-1873.
94. Siemens ADVIA Centaur enhanced liver fibrosis (ELF) test specifications 2013, Siemens Healthcare Diagnostics Inc.
95. Poynard T., Ratziu V., Naveau S., et al. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005, 4:10.
96. Parkes J., Guha I.N., Roderick P., Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006, 44:462-474.
97. Sebastiani G., Vario A., Guido M., et al. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol 2006, 44:686-693.
98. Gressner O.A., Beer N., Jodlowski A., Gressner A.M. Impact of quality control accepted inter-laboratory variations on calculated fibrotest/actitest scores for the non-invasive biochemical assessment of liver fibrosis. Clin Chim Acta 2009, 409:90-95.
99. Rosenthal-Allieri M.A., Peritore M.L., Tran A., Halfon P., Benzaken S., Bernard A. Analytical variability of the fibrotest proteins. Clin Biochem 2005, 38:473-478.
100. Gao Z., McAlister V.C., Williams G.M. Repopulation of liver endothelium by bone-marrow-derived cells. Lancet 2001, 357:932-933.
101. Fujii H., Hirose T., Oe S., et al. Contribution of bone marrow cells to liver regeneration after partial hepatectomy in mice. J Hepatol 2002, 36:653-659.
102. Baba S., Fujii H., Hirose T., et al. Commitment of bone marrow cells to hepatic stellate cells in mouse. J Hepatol 2004, 40:255-260.
103. Russo F.P., Alison M.R., Bigger B.W., et al. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006, 130:1807-1821.
104. Forbes S.J., Russo F.P., Rey V., et al. A significant proportion of myofibroblasts are of bone marrow origin in human liver fibrosis. Gastroenterology 2004, 126:955-963.
105. Kisseleva T., Uchinami H., Feirt N., et al. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J Hepatol 2006, 45:429-438.
106. Quan T.E., Cowper S.E., Bucala R. The role of circulating fibrocytes in fibrosis. Curr Rheumatol Rep 2006, 8:145-150.
107. Abe R., Donnelly S.C., Peng T., Bucala R., Metz C.N. Peripheral blood fibrocytes: differentiation pathway and migration to wound sites. J Immunol 2001, 166:7556-7562.
108. Quan T.E., Cowper S., Wu S.P., Bockenstedt L.K., Bucala R. Circulating fibrocytes: collagen-secreting cells of the peripheral blood. Int J Biochem Cell Biol 2004, 36:598-606.
109. Ishii G., Sangai T., Sugiyama K., et al. In vivo characterization of bone marrow-derived fibroblasts recruited into fibrotic lesions. Stem Cells 2005, 23:699-706.
110. Higashiyama R., Inagaki Y., Hong Y.Y., et al. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007, 45:213-222.
111. Marra F. Hepatic stellate cells and the regulation of liver inflammation. J Hepatol 1999, 31:1120-1130.
112. Romagnani P., Lasagni L., Romagnani S. Peripheral blood as a source of stem cells for regenerative medicine. Expert Opin Biol Ther 2006, 6:193-202.
113. Ruhnke M., Nussler A.K., Ungefroren H., et al. Human monocyte-derived neohepatocytes: a promising alternative to primary human hepatocytes for autologous cell therapy. Transplantation 2005, 79:1097-1103.
114. Ruhnke M., Ungefroren H., Nussler A., et al. Differentiation of in vitro-modified human peripheral blood monocytes into hepatocyte-like and pancreatic islet-like cells. Gastroenterology 2005, 128:1774-1786.
115. Pinzani M., Abboud H.E., Gesualdo L., Abboud S.L. Regulation of macrophage colony-stimulating factor in liver fat-storing cells by peptide growth factors. Am J Physiol 1992, 262:C876-C881.
116. Marra F., Valente A.J., Pinzani M., Abboud H.E. Cultured human liver fat-storing cells produce monocyte chemotactic protein-1 regulation by proinflammatory cytokines. J Clin Invest 1993, 92:1674-1680.
117. Sprenger H., Kaufmann A., Garn H., Lahme B., Gemsa D., Gressner A.M. Induction of neutrophil-attracting chemokines in transforming rat hepatic stellate cells. Gastroenterology 1997, 113:277-285.
118. Marra F., DeFranco R., Grappone C., et al. Increased expression of monocyte chemotactic protein-1 during active hepatic fibrogenesis: correlation with monocyte infiltration. Am J Pathol 1998, 152:423-430.
119. Pilling D., Buckley C.D., Salmon M., Gomer R.H. Inhibition of fibrocyte differentiation by serum amyloid P. J Immunol 2003, 171:5537-5546.
120. Pilling D., Roife D., Wang M., Crawford J.R., Travis E.L., Gomer R.H. Keystone symposia on molecular and cellular biology - Abstract book 2007.
121. Lee J.M., Dedhar S., Kalluri R., Thompson E.W. The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 2006, 172:973-981.
122. Kalluri R., Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003, 112:1776-1784.
123. Karasek M.A. Does transformation of microvascular endothelial cells into myofibroblasts play a key role in the etiology and pathology of fibrotic disease?. Med Hypotheses 2007, 68:650-655.
124. Kaimori A., Potter J., Kaimori J.Y., Wang C., Mezey E., Koteish A. Transforming growth factor-beta1 induces an epithelial-to-mesenchymal transition state in mouse hepatocytes in vitro. J Biol Chem 2007, 282:22089-22101.
125. Robertson H., Kirby J.A., Yip W.W., Jones D.E., Burt A.D. Biliary epithelial-mesenchymal transition in posttransplantation recurrence of primary biliary cirrhosis. Hepatology 2007, 45:977-981.
126. Rygiel K.A., Robertson H., Marshall H.L., et al. Epithelial-mesenchymal transition contributes to portal tract fibrogenesis during human chronic liver disease. Lab Invest 2008, 88:112-123.
127. Kinnman N., Francoz C., Barbu V., et al. The myofibroblastic conversion of peribiliary fibrogenic cells distinct from hepatic stellate cells is stimulated by platelet-derived growth factor during liver fibrogenesis. Lab Invest 2003, 83:163-173.
128. Beaussier M., Wendum D., Schiffer E., et al. Prominent contribution of portal mesenchymal cells to liver fibrosis in ischemic and obstructive cholestatic injuries. Lab Invest 2007, 87:292-303.
129. Ramadori G., Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004, 84:153-159.
130. Yang Y., Pan X., Lei W., et al. Regulation of transforming growth factor-beta 1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3. Cancer Res 2006, 66:8617-8624.
131. Del Castillo G., Murillo M.M., Alvarez-Barrientos A., et al. Autocrine production of TGF-beta confers resistance to apoptosis after an epithelial-mesenchymal transition process in hepatocytes: role of EGF receptor ligands. Exp Cell Res 2006, 312:2860-2871.
132. Vega S., Morales A.V., Ocana O.H., Valdes F., Fabregat I., Nieto M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev 2004, 18:1131-1143.
133. Zeisberg M., Hanai J., Sugimoto H., et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med 2003, 9:964-968.
134. Sugimoto H., Yang C., LeBleu V.S., et al. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 2007, 21:256-264.
135. Wang S., Hirschberg R. Bone morphogenetic protein-7 signals opposing transforming growth factor beta in mesangial cells. J Biol Chem 2004, 279:23200-23206.
136. ten Dijke P., Hill C.S. New insights into TGF-beta-Smad signalling. Trends Biochem Sci 2004, 29:265-273.
137. Neilson E.G. Setting a trap for tissue fibrosis. Nat Med 2005, 11:373-374.
138. Gressner A.M., Yagmur E., Lahme B., Gressner O., Stanzel S. Connective tissue growth factor in serum as a new candidate test for assessment of hepatic fibrosis. Clin Chem 2006, 52:1815-1817.
139. Leask A., Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J Cell Sci 2006, 119:4803-4810.
140. Abreu J.G., Ketpura N.I., Reversade B., De Robertis E.M. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat Cell Biol 2002, 4:599-604.
141. Gressner O.A., Lahme B., Demirci I., Gressner A.M., Weiskirchen R. Differential effects of TGF-beta on connective tissue growth factor (CTGF/CCN2) expression in hepatic stellate cells and hepatocytes. J Hepatol 2007, 47:699-710.
142. Rachfal A.W., Brigstock D.R. Connective tissue growth factor (CTGF/CCN2) in hepatic fibrosis. Hepatol Res 2003, 26:1-9.
143. Abou-Shady M., Friess H., Zimmermann A., et al. Connective tissue growth factor in human liver cirrhosis. Liver 2000, 20:296-304.
144. Paradis V., Dargere D., Vidaud M., et al. Expression of connective tissue growth factor in experimental rat and human liver fibrosis. Hepatology 1999, 30:968-976.
145. Blom I.E., Goldschmeding R., Leask A. Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?. Matrix Biol 2002, 21:473-482.
146. Li G., Xie Q., Shi Y., et al. Inhibition of connective tissue growth factor by siRNA prevents liver fibrosis in rats. J Gene Med 2006, 8:889-900.
147. George J., Tsutsumi M. siRNA-mediated knockdown of connective tissue growth factor prevents N-nitrosodimethylamine-induced hepatic fibrosis in rats. Gene Ther 2007, 14:790-803.
148. Gressner O.A., Fang M., Li H., Lu L.G., Gressner A.M., Gao C.F. Connective tissue growth factor (CTGF/CCN2) in serum is an indicator of fibrogenic progression and malignant transformation in patients with chronic hepatitis B infection. Clin Chim Acta 2013, 421:126-131.
149. Kovalenko E., Tacke F., Gressner O.A., et al. Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat 2009, 16:612-620.
150. Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant 2006, 21:568-573.
151. Saitou Y., Shiraki K., Yamanaka Y., et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005, 11:476-481.
152. Tran A., Benzaken S., Saint-Paul M.C., et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000, 12:989-993.
153. Kuhn J., Prante C., Schon S., Gotting C., Kleesiek K. Measurement of fibrosis marker xylosyltransferase I activity by HPLC electrospray ionization tandem mass spectrometry. Clin Chem 2006, 52:2243-2249.
154. Gressner A.M. Activation of proteoglycan synthesis in injured liver-a brief review of molecular and cellular aspects. Eur J Clin Chem Clin Biochem 1994, 32:225-237.
155. Poon T.C., Hui A.Y., Chan H.L., et al. Prediction of liver fibrosis and cirrhosis in chronic hepatitis B infection by serum proteomic fingerprinting: a pilot study. Clin Chem 2005, 51:328-335.
156. Callewaert N., Van Vlierberghe H., Van Hecke A., Laroy W., Delanghe J., Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat Med 2004, 10:429-434.
157. Mardini H., Record C. Detection assessment and monitoring of hepatic fibrosis: biochemistry or biopsy?. Ann Clin Biochem 2005, 42:441-447.
158. Kubota A., Okamura S., Omori F., et al. High serum levels of granulocyte-macrophage colony-stimulating factor in patients with liver cirrhosis and granulocytopenia. Clin Lab Haematol 1995, 17:61-63.
159. Yannaki E., Athanasiou E., Xagorari A., et al. G-CSF-primed hematopoietic stem cells or G-CSF per se accelerate recovery and improve survival after liver injury, predominantly by promoting endogenous repair programs. Exp Hematol 2005, 33:108-119.
160. Liu X., Hu H., Yin J.Q. Therapeutic strategies against TGF-beta signaling pathway in hepatic fibrosis. Liver Int 2006, 26:8-22.
161. Gressner A.M., Weiskirchen R. The tightrope of therapeutic suppression of active transforming growth factor-beta: high enough to fall deeply?. J Hepatol 2003, 39:856-859.
162. Kinoshita K., Iimuro Y., Otogawa K., et al. Adenovirus-mediated expression of BMP-7 suppresses the development of liver fibrosis in rats. Gut 2007, 56:706-714.
163. Zeisberg M., Shah A.A., Kalluri R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J Biol Chem 2005, 280:8094-8100.
164. Liu D.Y., Jacob C.T., Zhang W., et al. Anti-CTGF (CCN2) human antibody therapy: FG-3019 prevents and reverses renal and cardiovascular pathologies in animal models of diabetic complications. Keystone symposium on molecular and cellular biology - Abstract book 2007, 33.